We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sepracor Gets DDMAC Letter for Lunesta DTC TV Ad
Sepracor Gets DDMAC Letter for Lunesta DTC TV Ad
June 18, 2010
Sepracor has received an untitled letter from the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) for a direct-to-consumer (DTC) TV ad that makes unsubstantiated claims, including superiority, about its insomnia drug Lunesta.